← All trials
NCT01857453
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2013
- Primary completion
- Oct 1, 2017
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 97
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of LorraineLead sponsor
- Curie InstituteCollaborator
- University of LorraineOverall official - principal investigator
- University of ReimsCollaborator
- Centre Paul StraussCollaborator
- Centre Hospitalier Universitaire de NīmesCollaborator
- Centre Georges Francois LeclercCollaborator
- Centre Leon BerardCollaborator
- Center Eugene MarquisCollaborator
- University of BordeauxCollaborator
- University of ParisCollaborator
- University of Caen-NormandieCollaborator
- University of Picardie Jules VerneCollaborator
- Hospices Civils de ColmarCollaborator
- Institut Gustave RoussyCollaborator
- University of MontpellierCollaborator
- University of NantesCollaborator
- University of LilleCollaborator
- University of ToulouseCollaborator
- University of Nice Sophia AntipolisCollaborator
- Aix-University of MarseilleCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.